본문 바로가기 주메뉴 바로가기

제품소개

제품상세페이지

Accegen

[Accegen] Daudi

Cat-No. ABC-TC0204


upload_image


미국 Accegen은 생명과학 연구와 의약품 개발을 지원하기 위해 다양한 세포주와 생물학적 제품을 제공하는 바이오 제품 제조 기업입니다.




제품 설명


Daudi




제품 번호


ABC-TC0204




제품 특징


The Daudi cell line, derived from a 16-year-old male Burkitt’s Lymphoma patient of African descent in 1967, primarily comprises B lymphoblasts and is characterized by its EBV-positive status along with the expression of mRNA for the proto-oncogene BCL2. Notably, these cells exhibit a deficiency in surface expression of HLA-ABC molecules due to the absence of beta-2-microglobulin, which is essential for the proper intracellular folding and processing of MHC class I molecules within the endoplasmic reticulum. It is advisable to employ a subculturing strategy with a split ratio ranging from 1:2 to 1:4 every 2-4 days, although initial growth of these cells may be relatively slow.

 

Why choose Daudi from AcceGen?

Daudi cells from AcceGen exhibit high viability and quality, ensuring robust experimental results. They are provided in a sterile state and rigorously screened for the absence of contaminants, including bacteria, yeast, fungi, mycoplasma, HIV, HBV, and HCV. Moreover, their identity is confirmed through STR analysis, further ensuring the reliability and authenticity of these cells for research applications.


These well-characterized Daudi B lymphoblasts have been extensively used in the study of leukemogenesis, serving as a valuable model system for understanding the intricacies of B cell biology. Their utility extends to the analysis of B cell surface antigens, enabling the exploration of antigen expression and characterization. Moreover, Daudi cells are employed in the testing of cytotoxic drugs, mutational analysis, and investigations into apoptotic mechanisms, contributing significantly to research across these pivotal areas in oncology and immunology.




Accegen의 모든 제품들을 만나 보세요!

 

PRODUCTS